IN2014DN00200A - - Google Patents

Info

Publication number
IN2014DN00200A
IN2014DN00200A IN200DEN2014A IN2014DN00200A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A IN 200DEN2014 A IN200DEN2014 A IN 200DEN2014A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A
Authority
IN
India
Prior art keywords
riluzole
subject
methods
reducing
auc24h
Prior art date
Application number
Other languages
English (en)
Inventor
Jesse Cedarbaum
John Mao
Fady Malik
Andrew A Wolff
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of IN2014DN00200A publication Critical patent/IN2014DN00200A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN200DEN2014 2011-07-13 2012-07-12 IN2014DN00200A (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US201261637770P 2012-04-24 2012-04-24
US201261637759P 2012-04-24 2012-04-24
US201261646699P 2012-05-14 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Publications (1)

Publication Number Publication Date
IN2014DN00200A true IN2014DN00200A (el) 2015-06-05

Family

ID=47506929

Family Applications (1)

Application Number Title Priority Date Filing Date
IN200DEN2014 IN2014DN00200A (el) 2011-07-13 2012-07-12

Country Status (15)

Country Link
US (1) US10272082B2 (el)
EP (1) EP2731611B1 (el)
JP (2) JP6145946B2 (el)
KR (1) KR101951220B1 (el)
CN (2) CN104039148A (el)
AU (2) AU2012281042B2 (el)
BR (1) BR112014000742A2 (el)
CA (1) CA2849213A1 (el)
EA (2) EA201791043A1 (el)
HK (1) HK1197178A1 (el)
IL (1) IL230391B (el)
IN (1) IN2014DN00200A (el)
SG (1) SG10201605707UA (el)
WO (1) WO2013010015A2 (el)
ZA (1) ZA201400236B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
HRP20220183T1 (hr) 2014-04-29 2022-04-29 Cytokinetics, Inc. Postupci smanjivanja propadanja vitalnog kapaciteta
EA038518B1 (ru) * 2014-11-21 2021-09-09 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Сублингвальный препарат рилузола
CN107735077A (zh) * 2014-11-21 2018-02-23 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN108883108B (zh) 2016-03-25 2021-08-06 Ab科学有限公司 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途
CA3151459A1 (en) * 2019-09-20 2021-03-25 Ana PEREIRA Controlled release formulations of riluzole and their uses

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
SK18542000A3 (sk) 1998-06-04 2001-12-03 Abbott Laboratories Protizápalové zlúčeniny inhibujúce bunkovú adhéziu
JP2003511456A (ja) 1999-10-08 2003-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二環状イミダゾ−5−イル−アミン誘導体
BR0014818A (pt) 1999-10-08 2002-06-18 Gruenenthal Gmbh Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
US20030083318A1 (en) 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
AU2004263080B2 (en) 2003-06-26 2008-12-18 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
MXPA06007054A (es) 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
WO2005072412A2 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7608622B2 (en) 2004-09-24 2009-10-27 Janssen Pharmaceutica Nv Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP2008530212A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Cxcr3アンタゴニスト活性を有するピペラジン−ピペリジン
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US20100173930A1 (en) 2006-08-01 2010-07-08 Alex Muci Certain Chemical Entities, Compositions and Methods
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
PT2583970E (pt) * 2006-08-02 2016-02-08 Cytokinetics Inc Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
KR20140104060A (ko) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
BRPI0806898A2 (pt) 2007-01-19 2015-07-14 Ardea Biosciences Inc Inibidores de mek
EP2139478A4 (en) 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
EP2018854A1 (en) 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
EP2244711A4 (en) 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
CA2730473A1 (en) 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
MX2011013577A (es) * 2009-06-19 2012-04-10 Knopp Neurosciences Inc Composiciones y metodos para tratar esclerosis lateral amiotrofica.
SG11201406270YA (en) 2012-04-02 2014-10-30 Cytokinetics Inc Methods for improving diaphragm function
EP2836590A4 (en) 2012-04-11 2016-04-13 Cytokinetics Inc METHOD FOR IMPROVING THE RESISTANCE TO SKELETON MUSCULAR FEEDING
HRP20220183T1 (hr) 2014-04-29 2022-04-29 Cytokinetics, Inc. Postupci smanjivanja propadanja vitalnog kapaciteta

Also Published As

Publication number Publication date
BR112014000742A2 (pt) 2016-08-23
EA201791043A1 (ru) 2017-09-29
HK1197178A1 (en) 2015-01-09
CA2849213A1 (en) 2013-01-17
JP2017128610A (ja) 2017-07-27
WO2013010015A2 (en) 2013-01-17
JP2014520856A (ja) 2014-08-25
US20140243344A1 (en) 2014-08-28
EP2731611B1 (en) 2019-09-18
WO2013010015A3 (en) 2014-05-15
EP2731611A4 (en) 2015-02-18
CN104039148A (zh) 2014-09-10
EA201490011A1 (ru) 2014-08-29
EA028060B1 (ru) 2017-10-31
AU2016244263A1 (en) 2016-11-03
CN109316480A (zh) 2019-02-12
NZ619924A (en) 2016-02-26
AU2012281042B2 (en) 2016-07-14
KR20140074270A (ko) 2014-06-17
IL230391B (en) 2019-03-31
US10272082B2 (en) 2019-04-30
ZA201400236B (en) 2014-10-29
AU2012281042A1 (en) 2014-01-30
SG10201605707UA (en) 2016-09-29
EP2731611A2 (en) 2014-05-21
KR101951220B1 (ko) 2019-02-22
JP6145946B2 (ja) 2017-06-14

Similar Documents

Publication Publication Date Title
IN2014DN00200A (el)
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MY196418A (en) Therapeutically Active Compounds and Their Methods of use
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
WO2012093258A3 (en) Irf5- related treatment and screening
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
EA201490614A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB
EA201391591A1 (ru) Лечение множественной миеломы
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
MX2015004389A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods.
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
CA2866819C (en) Method for treating inflammation
NZ597115A (en) Method of treating age related disorders with fujimycin
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
MX2014013503A (es) Metodo para inducir actividad udp-glucuronosiltransferasa utilizando pterostilbeno.
WO2008129239A3 (en) Use of agents that inhibit homologous recombination for the treatment of cancer
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
UA67100U (ru) Способ лечения переднего эндогенного увеита
MX2022002947A (es) Avocatina b para el tratamiento de enfermedades y afecciones.
WO2011139368A3 (en) Methods of treatment of inflammatory diseases
IN2014DN05769A (el)